Comparing Jakafi vs Ruxolitinib
| Jakafi (ruxolitinib) | Ruxolitinib |
|
|---|
| Jakafi (ruxolitinib) | Ruxolitinib |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Polycythemia Vera, Myelofibrosis, Graft Versus Host Disease, Myeloproliferative Disorders. Jakafi may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Polycythemia Vera, Myelofibrosis, Graft Versus Host Disease, Myeloproliferative Disorders. Ruxolitinib may also be used for purposes not listed in this medication guide. |
Related suggestions Polycythemia Vera
Myelofibrosis
Graft Versus Host Disease
|
|||||||
| More about Jakafi (ruxolitinib) | More about Ruxolitinib | ||||||||
| Ratings & Reviews | |||||||||
|
Jakafi has an average rating of 7.5 out of 10 from a total of 33 ratings on Drugs.com. 67% of reviewers reported a positive effect, while 15% reported a negative effect. |
Ruxolitinib has an average rating of 7.3 out of 10 from a total of 43 ratings on Drugs.com. 65% of reviewers reported a positive effect, while 16% reported a negative effect. |
||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||
|
View all Jakafi side effects |
View all Ruxolitinib side effects |
||||||||
| Drug Class | |||||||||
| Generic Availability | |||||||||
|
N/A |
|||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||
View all Jakafi prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||
| Dosage Forms | |||||||||
|
N/A |
||||||||
| Brand Names | |||||||||
|
N/A |
Jakafi | ||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||
|
5.8 hours |
5.8 hours |
||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | |||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||
| Drug Interactions | |||||||||
|
A total of 515 drugs are known to interact with Jakafi:
|
A total of 515 drugs are known to interact with Ruxolitinib:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||
|
|
||||||||
| Disease Interactions | |||||||||
| First Approval Date | |||||||||
|
November 16, 2011 |
November 16, 2011 |
||||||||
| WADA Class View classifications | |||||||||
|
N/A |
N/A |
||||||||
| More Information | |||||||||
| Patient Resources | |||||||||
| Professional Resources | |||||||||
| Related Treatment Guide | |||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.